Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CD34+-enriched HSPCs transduced with LV vector carrying TCIRG1 gene RP-L401

A preparation of autologous CD34+-enriched hematopoietic stem and progenitor cells (HSPCs) from mobilized peripheral blood of patients with infantile malignant osteopetrosis (IMO) that are transduced ex vivo with a lentiviral (LV) vector carrying the T-cell immune regulator 1 (TCIRG1) gene, with potential to restore TCIRG1 expression and function. Upon re-infusion of autologous CD34+-enriched HSPCs transduced with LV vector carrying TCIRG1 gene RP-L401 back into the patient, these cells express functional TCIRG1 gene. Mutations in the TCIRG1 gene, found in some patients with IMO, lead to functional impairment of the proton pump of the osteoclast.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CD34+ HSPCs transduced with LV vector encoding TCIRG1 gene RP-L401
autologous CD34+-enriched hematopoietic stem and progenitor cells transduced with lentiviral vector carrying TCIRG1 gene RP-L401
autologous CD34+-enriched HSPCs-expressing TCIRG1 gene RP-L401
Code name:RP L401
RP-L401
RPL401
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search